BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax of $5.19 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-09-30 was $5.19M, a 822.95% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-06-30 was $5.16M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-03-31 was -$4.74M, a 634.27% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2014-12-31 was $27.00K, a 96.97% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2014 was -$1.01M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2013 was -$77.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2015-09-30 | $5.19M 10-Q · filed 2015-11-02 | $10.35M derived: sum of 2 quarters · filed 2015-11-02 | $15.08M 10-Q · filed 2015-11-02 | $5.63M derived: sum of 4 quarters · filed 2015-11-02 | |||
| 2015-06-30 | $5.16M 10-Q · filed 2015-08-05 | $9.90M 10-Q · filed 2015-08-05 | $446.00K derived: sum of 3 quarters · filed 2015-08-05 | $1.01M derived: sum of 4 quarters · filed 2015-11-02 | |||
| 2015-03-31 | -$4.74M 10-Q · filed 2015-05-05 | -$4.71M derived: sum of 2 quarters · filed 2015-05-05 | -$4.15M derived: sum of 3 quarters · filed 2015-11-02 | -$4.86M derived: sum of 4 quarters · filed 2015-11-02 | |||
| 2014-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $589.00K derived: sum of 2 quarters · filed 2015-11-02 | -$121.00K derived: sum of 3 quarters · filed 2015-11-02 | -$1.01M 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $562.00K 10-Q · filed 2015-11-02 | -$562.00K 10-Q · filed 2014-10-28 | -$148.00K derived: sum of 2 quarters · filed 2015-11-02 | -$1.03M 10-Q · filed 2015-11-02 | $1.03M 10-Q · filed 2014-10-28 | $1.63M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2014-06-30 | -$710.00K 10-Q · filed 2015-08-05 | $710.00K 10-Q · filed 2014-07-31 | -$1.60M 10-Q · filed 2015-08-05 | $1.60M 10-Q · filed 2014-07-31 | $1.07M derived: sum of 3 quarters · filed 2015-08-05 | $967.00K derived: sum of 4 quarters · filed 2015-08-05 | |
| 2014-03-31 | $887.00K 10-Q · filed 2015-05-05 | $1.78M derived: sum of 2 quarters · filed 2015-05-05 | $1.68M derived: sum of 3 quarters · filed 2015-05-05 | $1.31M derived: sum of 4 quarters · filed 2015-05-05 | |||
| 2013-12-31 | $891.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $790.00K derived: sum of 2 quarters · filed 2015-03-02 | $422.00K derived: sum of 3 quarters · filed 2015-03-02 | -$77.00K 10-K · filed 2015-03-02 | |||
| 2013-09-30 | -$101.00K 10-Q · filed 2014-10-28 | -$469.00K derived: sum of 2 quarters · filed 2014-10-28 | -$968.00K 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | -$368.00K 10-Q · filed 2014-07-31 | -$867.00K 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | -$499.00K 10-Q · filed 2014-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |